{"id":"full-dose-olanzapine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation"},{"rate":"15-25","effect":"Metabolic syndrome / hyperglycemia"},{"rate":"15-20","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Akathisia"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"5-15","effect":"Prolactin elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its broader clinical effects.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:03.476Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Treatment-resistant depression (adjunctive use)"}]},"trialDetails":[{"nctId":"NCT02704962","phase":"PHASE4","title":"Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine","status":"COMPLETED","sponsor":"Kaohsiung Kai-Suan Psychiatric Hospital","startDate":"2012-01","conditions":"Schizophrenia","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["polypharmacy"],"phase":"marketed","status":"active","brandName":"full-dose olanzapine","genericName":"full-dose olanzapine","companyName":"Kaohsiung Kai-Suan Psychiatric Hospital","companyId":"kaohsiung-kai-suan-psychiatric-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Full-dose olanzapine is used to treat schizophrenia. It works as a serotonin 2a (5-HT2a) receptor antagonist, a type of small molecule that blocks the action of serotonin at this receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}